The Southwest Oncology Group Cancer Research Program of the University of Texas Health Science Center at San Antonio will be carried out in cooperation with other member institutions, CCOPs, CGOPs, UCOPs and High- Priority institutions of the Southwest Oncology Group. This program shall seek to recruit patient subjects to multidisciplinary clinical trials and cancer control programs for the management of malignant conditions and conditions at high risk of malignancy. The Principal Investigator and other investigators bring 15 years experience in the performance of cooperative therapeutic research to this program. The program involves collaboration from investigators representing the disciplines of Medical Oncology, Hematology, Radiation Oncology, Surgical Oncology, and Pathology. Estimated accrual exceeds 200 patients yearly for the duration of this program. The investigators named in this application contribute not only to the institutional Group activities but also to the scientific and administrative direction of the southwest Oncology Group as a whole. Charles A. Coltman, Jr., M.D., is Chairman of the Group; Mace L. Rothenberg, M.D., is Executive Officer of the Group; Geoffrey R. Weiss, M.D., and Noboru Oishi, M.D., are Associate Executive Officers of the Group; C. Kent Osborne, M.D., is Chairman of the Breast Cancer Committee; Anatolio B. Cruz, Jr., M.D., is Chairman of the Surgical Quality Control Committee; David H. Boldt, M.D., is Director of the Central Acute Lymphoblastic Leukemia Phenotyping Laboratory and Repository; William L. McGuire, M.D., is Director of the Central Breast Cancer Prognostic Factor Laboratory; Michael F. Sarosdy, M.D., is Chairman of the Testis Cancer Subcommittee. The University of Texas Health Science Center at San Antonio is a major contributor to patient accrual, scientific programs and administrative activities at both the institutional level and Groupwide. In the past four years of Group activities, our institution has served 708 patients (in the past year, 16% Hispanic/Mexican Americans and 45% women) by enrollment to therapeutic cooperative clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA022433-20
Application #
2007236
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1997-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
20
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8

Showing the most recent 10 out of 257 publications